• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Chicken Soup For The Soul Entertainment Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket

    4/5/23 8:16:11 AM ET
    $ADXN
    $BFRG
    $BRDS
    $CSSE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADXN alert in real time by email

    Gainers

    • RiceBran Technologies (NASDAQ:RIBT) gained 43.1% to $1.33 in pre-market trading after gaining 3% on Tuesday.
    • Addex Therapeutics Ltd (NASDAQ:ADXN) jumped 35.4% to $1.25 in pre-market trading. Addex said it completed $5 million equity financing.
    • Millennium Group International Holdings Limited (NASDAQ:MGIH) shares climbed 25.8% to $4.04 in pre-market trading after dipping around 20% on Tuesday.
    • Ebang International Holdings Inc. (NASDAQ:EBON) gained 17.8% to $7.00 in pre-market trading after dropping 15% on Tuesday.
    • Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSE) gained 14.1% to $1.86 in pre-market trading. Chicken Soup For The Soul Entertainment’s Form4 filing showed CEO bought 1.8 million shares of common stock.
    • Virios Therapeutics, Inc. (NASDAQ:VIRI) climbed 12.2% to $0.3876 in pre-market trading after dropping 4% on Tuesday. The company recently posted a narrower-than-expected quarterly loss.
    • InflaRx N.V. (NASDAQ:IFRX) gained 10.8% to $4.18 in pre-market trading. InflaRx shares jumped 84% on Tuesday after the company announced it received FDA Emergency Use Authorization for Gohibic for the treatment of critically-ill COVID-19 patients.
    • Bird Global, Inc. (NYSE:BRDS) gained 9.3% to $0.2415 in pre-market trading after dropping around 15% on Tuesday. Bird Global recently announced the purchase of shares by management and directors.
    • Pyxis Oncology, Inc. (NASDAQ:PYXS) climbed 9.3% to $3.75 in pre-market trading after dropping more than 15% on Tuesday.
    • Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) surged 7.2% to $0.7451 in pre-market trading after dropping 9% on Tuesday.

    Losers

    • Secoo Holding Limited (NASDAQ:SECO) fell 19.2% to $1.18 in pre-market trading after jumping 143% on Tuesday.
    • Nuvve Holding Corp. (NASDAQ:NVVE) fell 17.4% to $0.6490 in pre-market trading after gaining over 30% on Tuesday. Nuvve Holding recently posted better-than-expected quarterly sales.
    • First Wave BioPharma, Inc. (NASDAQ:FWBI) shares dropped 15.6% to $2.27 in pre-market trading after gaining 11% on Tuesday. First Wave BioPharma recently announced a $4.0 million private placement priced at-the-market under Nasdaq rules.
    • Sono Group N.V. (NASDAQ:SEV) shares fell 12.4% to $0.2980 in pre-market trading after dropping 6% on Tuesday.
    • Histogen Inc. (NASDAQ:HSTO) fell 11.7% to $1.06 in pre-market. Histogen reported exclusive intellectual property license agreement with Johns Hopkins University.
    • DLocal Limited (NASDAQ:DLO) fell 11.4% to $15.00 in pre-market trading after the company posted weaker-than-expected Q4 results.
    • The NFT Gaming Company, Inc. (NASDAQ:NFTG) fell 11.4% to $1.77 in pre-market trading. The NFT Gaming Company shares gained around 50% on Tuesday after the company provided a shareholder update on game launches, AI, Gaxos platform and other initiatives.
    • Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) fell 10.7% to $5.36 in pre-market trading. Bullfrog AI shares jumped around 28% on Tuesday after the company announced a worldwide license agreement with Johns Hopkins University Applied Physics Laboratory for use of patented technology powering the company's bfLEAP platform..
    • Assure Holdings Corp. (NASDAQ:IONM) fell 9.7% to $3.34 in pre-market trading. Assure Hldgs, on Monday, posted a FY loss of $40.06 per share.
    • Oncternal Therapeutics, Inc. (NASDAQ:ONCT) shares fell 8.2% to $0.3125 in pre-market trading after dropping 57% on Tuesday. Oncternal Therapeutics said it will suspend Phase 3 and the Phase 1/2 studies of zilovertamab in combination with ibrutinib, citing the rapidly changing commercial landscape for Bruton's tyrosine kinase inhibitors (BTK inhibitors).

    Now Read This: Top 4 Materials Stocks That Set To Fly In April

    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $BFRG
    $BRDS
    $CSSE

    CompanyDatePrice TargetRatingAnalyst
    Aptera Motors Corp.
    $SEV
    3/9/2026$10.00Buy
    Alliance Global Partners
    DLocal Limited
    $DLO
    12/17/2025$21.00Outperform
    Itau BBA
    DLocal Limited
    $DLO
    12/11/2025$16.00Hold → Buy
    Truist
    InflaRx N.V.
    $IFRX
    12/3/2025$2.00Outperform → Market Perform
    Leerink Partners
    Pyxis Oncology Inc.
    $PYXS
    11/3/2025$9.00Buy
    Stifel
    DLocal Limited
    $DLO
    10/14/2025$19.00Neutral → Buy
    Goldman
    Pyxis Oncology Inc.
    $PYXS
    9/4/2025$5.00Buy
    Guggenheim
    InflaRx N.V.
    $IFRX
    9/2/2025$6.00Buy
    H.C. Wainwright
    More analyst ratings

    $ADXN
    $BFRG
    $BRDS
    $CSSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Smith Ted C. bought $20,606 worth of shares (7,155 units at $2.88), increasing direct ownership by 126% to 12,855 units (SEC Form 4)

    4 - Nuvve Holding Corp. (0001836875) (Issuer)

    12/23/24 5:09:54 PM ET
    $NVVE
    Electrical Products
    Industrials

    President and COO Smith Ted C. bought $10,802 worth of shares (3,928 units at $2.75), increasing direct ownership by 222% to 5,700 units (SEC Form 4)

    4 - Nuvve Holding Corp. (0001836875) (Issuer)

    12/20/24 5:24:40 PM ET
    $NVVE
    Electrical Products
    Industrials

    CFO & COO Connealy Pamela Ann bought $174,364 worth of shares (88,850 units at $1.96) (SEC Form 4)

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    11/27/24 5:09:59 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $BFRG
    $BRDS
    $CSSE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvve Provides Fourth Quarter and Full Year 2025 Financial Update

    Investor Conference Call to be Held Today at 5:00 PM Eastern Time (2:00 PM PT) Nuvve Holding Corp. (Nuvve) (NASDAQ:NVVE), a global leader in advanced energy storage, grid modernization solutions and vehicle-to-grid (V2G) technology, today provided a fourth quarter and full-year 2025 financial update. Fourth Quarter Highlights and Recent Developments We raised $8.1 million in gross proceeds through a private preferred stock offering, warrants exercises and debt obligations during the fourth quarter of 2025 to support our operations and growth initiatives Total revenues were $1.9 million for the fourth quarter of 2025 compared to $1.8 million for the fourth quarter 2024 Gross pro

    3/31/26 4:30:00 PM ET
    $NVVE
    Electrical Products
    Industrials

    dLocal to Report First Quarter 2026 Financial Results

    MONTEVIDEO, Uruguay, March 31, 2026 (GLOBE NEWSWIRE) -- DLocal Limited (NASDAQ:DLO, "dLocal" or the "Company")), a leading financial technology company powering payments across emerging markets, intends to release financial results for its first fiscal quarter ended March 31, 2026 on May 14, 2026 after market close. The Company will host a conference call and video webcast on May 14, 2026 at 6:00 p.m. Eastern Time. Please click here to pre-register for the conference call and obtain your dial in number and passcode. The live conference call can be also accessed via audio webcast at the investor relations section of the Company's website, at https://investor.dlocal.com/. An archive of the

    3/31/26 4:10:02 PM ET
    $DLO
    Real Estate

    InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium

    JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 Biotech Innovation Symposium. Details are as follows: Raymond James 2026 Biotech Innovation SymposiumApril 14, 2026, in New York, NYThe Company will hold one-on-one investor meetings. About InflaRxInflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement

    3/31/26 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $BFRG
    $BRDS
    $CSSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dupont Jakob

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    3/25/26 5:18:44 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Wadhane Jitendra

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    3/25/26 5:17:26 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Flavin John L

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    3/25/26 5:10:59 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $BFRG
    $BRDS
    $CSSE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Aptera Motors Corp. with a new price target

    Alliance Global Partners initiated coverage of Aptera Motors Corp. with a rating of Buy and set a new price target of $10.00

    3/9/26 9:28:24 AM ET
    $SEV
    Auto Manufacturing
    Industrials

    Itau BBA initiated coverage on dLocal Limited with a new price target

    Itau BBA initiated coverage of dLocal Limited with a rating of Outperform and set a new price target of $21.00

    12/17/25 9:18:01 AM ET
    $DLO
    Real Estate

    dLocal Limited upgraded by Truist with a new price target

    Truist upgraded dLocal Limited from Hold to Buy and set a new price target of $16.00

    12/11/25 8:44:49 AM ET
    $DLO
    Real Estate

    $ADXN
    $BFRG
    $BRDS
    $CSSE
    SEC Filings

    View All

    SEC Form EFFECT filed by Aptera Motors Corp.

    EFFECT - Aptera Motors Corp (0001786471) (Filer)

    4/3/26 12:15:11 AM ET
    $SEV
    Auto Manufacturing
    Industrials

    SEC Form 6-K filed by InflaRx N.V.

    6-K - InflaRx N.V. (0001708688) (Filer)

    4/2/26 4:19:19 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POS AM filed by Aptera Motors Corp.

    POS AM - Aptera Motors Corp (0001786471) (Filer)

    4/2/26 4:05:23 PM ET
    $SEV
    Auto Manufacturing
    Industrials

    $ADXN
    $BFRG
    $BRDS
    $CSSE
    Financials

    Live finance-specific insights

    View All

    dLocal to Report First Quarter 2026 Financial Results

    MONTEVIDEO, Uruguay, March 31, 2026 (GLOBE NEWSWIRE) -- DLocal Limited (NASDAQ:DLO, "dLocal" or the "Company")), a leading financial technology company powering payments across emerging markets, intends to release financial results for its first fiscal quarter ended March 31, 2026 on May 14, 2026 after market close. The Company will host a conference call and video webcast on May 14, 2026 at 6:00 p.m. Eastern Time. Please click here to pre-register for the conference call and obtain your dial in number and passcode. The live conference call can be also accessed via audio webcast at the investor relations section of the Company's website, at https://investor.dlocal.com/. An archive of the

    3/31/26 4:10:02 PM ET
    $DLO
    Real Estate

    Nuvve to Provide Fourth Quarter Ended December 31, 2025, Financial Update

    Investor Conference Call to be Held Tuesday, March 31, 2026, at 5:00 PM Eastern Time (2:00 PM PT) Nuvve Holding Corp. ("Nuvve") (NASDAQ:NVVE), a global leader in grid modernization and vehicle-to-grid (V2G) technology, will provide Fourth quarter ended December 31, 2025, update on Tuesday, March 31, 2026. Conference Call Details Nuvve will hold a conference call to review its financial results for the fourth quarter ended December 31, 2025, along with other company developments at 5:00 PM Eastern Time (2:00 PM PT), Tuesday, March 31, 2026. To participate in the call, please dial (888) 349-0097 or (412) 902-4245; Passcode: 7091129, or register for and listen via a live webcast, which

    3/26/26 8:00:00 AM ET
    $NVVE
    Electrical Products
    Industrials

    InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

    Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aRSubstantial progress made toward Phase 2b readiness for izicopan in hidradenitis suppurativa (HS)InflaRx actively reviewing and considering additional development in ANCA‑associated vasculitis (AAV)To broaden izicopan signal-finding activities and expedite proof-of-concept studies into additional indications in inflammation and immunology (I&I), InflaRx intends to conduct a pharmacokinetic (PK) bridging study in China this yearActive dialog with potential collaborators to expedite the Company's total pipeline development goals continuesInflaRx

    3/19/26 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $BFRG
    $BRDS
    $CSSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nuvve Holding Corp.

    SC 13G/A - Nuvve Holding Corp. (0001836875) (Subject)

    11/13/24 11:19:43 AM ET
    $NVVE
    Electrical Products
    Industrials

    Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

    SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

    11/12/24 11:53:51 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by DLocal Limited

    SC 13G/A - dLocal Ltd (0001846832) (Subject)

    11/12/24 9:55:17 AM ET
    $DLO
    Real Estate

    $ADXN
    $BFRG
    $BRDS
    $CSSE
    Leadership Updates

    Live Leadership Updates

    View All

    Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for mid-year 2026; to include patients treated with modified weight-based dosing and patients treated with total body weight dosing Updated data from MICVO Phase 1/2 dose escalation study in combination with KEYTRUDA® in 1L/2L+ R/M HNSCC on track for the second half of 2026 Announced appointment of Thomas Civik as Interim Chief Executive Officer Expected cash runway into the fourth quarter of 2026 BOSTO

    3/23/26 7:00:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

    BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology's Board of Directors since the Company's IPO and a highly experienced biotechnology executive with a proven track record in advancing cancer therapeutics, has been appointed Interim Chief Executive Officer, effective immediately. Lara S. Sullivan, M.D., has stepped down from her roles as President, Chief Executive Officer and Chief Medical Officer. With

    2/3/26 6:45:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aptera Motors Appoints Automotive Industry Veteran Tony Kirton as Chairman of the Board of Directors

    CARLSBAD, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aptera Motors Corp. (NASDAQ:SEV), a solar mobility company advancing ultra-efficient transportation, today announced that Tony Kirton has been appointed Chairman of the Board of Directors. Kirton brings more than four decades of global automotive leadership experience, having held senior executive and board roles across leading automotive brands including Volkswagen, Audi, and BMW. His appointment follows his service as an independent board director and supports Aptera's focus on disciplined governance and long-term value creation as the company prepares for production. "Over my career, I've seen many technologies promise transformation

    1/8/26 4:49:26 PM ET
    $SEV
    Auto Manufacturing
    Industrials